Skip to Main Content
Table 1.

Studies of HNSCCs by cancer site, geographic location of study, and overall prevalence of PV

SiteGeographic locationNo. studiesNo. casesOverall HPV prevalence (95% CI)
Oral cavity Australia, Canada, China, Cuba, Finland, France, Germany, India, Ireland, Italy, Japan, Korea, Netherlands, Norway, Poland, Spain, Slovenia, Sudan, Sweden, Switzerland, Taiwan, United Kingdom, United States, Venezuela 35 2,642 23.5 (21.9-25.1) 
Oropharynx Australia, Canada, Cuba, Finland, France, Germany, India, Ireland, Italy, Japan, Netherlands, Norway, Poland, Spain, Slovenia, Sudan, Sweden, Switzerland, United States 27 969 35.6 (32.6-38.7) 
Larynx* Canada, Cuba, Denmark, Finland, France, Germany, Greece, India, Italy, Japan, Netherlands, Norway, Spain, Slovenia, Sweden, Switzerland, United Kingdom, United States 35 1,435 24.0 (21.8-26.3) 
Overall As listed above 60 5,046 25.9 (24.7-27.2) 
SiteGeographic locationNo. studiesNo. casesOverall HPV prevalence (95% CI)
Oral cavity Australia, Canada, China, Cuba, Finland, France, Germany, India, Ireland, Italy, Japan, Korea, Netherlands, Norway, Poland, Spain, Slovenia, Sudan, Sweden, Switzerland, Taiwan, United Kingdom, United States, Venezuela 35 2,642 23.5 (21.9-25.1) 
Oropharynx Australia, Canada, Cuba, Finland, France, Germany, India, Ireland, Italy, Japan, Netherlands, Norway, Poland, Spain, Slovenia, Sudan, Sweden, Switzerland, United States 27 969 35.6 (32.6-38.7) 
Larynx* Canada, Cuba, Denmark, Finland, France, Germany, Greece, India, Italy, Japan, Netherlands, Norway, Spain, Slovenia, Sweden, Switzerland, United Kingdom, United States 35 1,435 24.0 (21.8-26.3) 
Overall As listed above 60 5,046 25.9 (24.7-27.2) 
*

Larynx includes cases of the hypopharynx.

Does not sum to total number of studies because some studies investigated multiple sites.

Close Modal

or Create an Account

Close Modal
Close Modal